Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Aftershocks Disrupt Production at Some Pharma Production Facilities
April 18, 2011
- Korosho to Introduce “Yellow Letter”for Patients
April 18, 2011
- Relaxation of Restrictions on Online Sale of OTC Drugs May Enter Agenda in May: President Kodama of JPA
April 18, 2011
- Gov't to Enforce 25% Power Cuts This Summer for Major Users Including Drug Makers
April 18, 2011
- Gov't Appeals to High Court in Iressa Case
April 18, 2011
- Taisho Acquires Hoepharma of Malaysia
April 18, 2011
- Korosho Calls on Industry to Come Up with Energy Conservation Plans
April 18, 2011
- FDA Approves 1st New Treatment for Late-stage Melanoma in Over a Decade: BMS
April 18, 2011
- Eiken Licenses LAMP Technology to OptiGene
April 18, 2011
- ASKA Begins Shipments of Thyradin Substitute
April 18, 2011
- Review Period for QAB149 for COPD Extended 3 Months by FDA
April 18, 2011
- MCM Negotiates Partnership with Clearstone of Canada in CLS Services
April 18, 2011
- Ajinomoto Obtains Domestic Rights to IBD Treatment from Dr Falk
April 18, 2011
- NEW PRODUCTS
April 18, 2011
- FDA Approves HCC Test System μTASWako i30: Wako Pure Chemical
April 18, 2011
- BioWa Licenses Potelligent to OBT
April 18, 2011
- Takeda, Heptares of UK Announce 2-Year Research Collaboration
April 18, 2011
- Eisai's Subsidiary Morphotek Acquires Tumor Targeting Assets from TransMolecular
April 18, 2011
- Sanofi-aventis Acquires Additional Nichi-Iko Shares
April 18, 2011
- BI 201335 NA Shows Favorable Results for Hepatitis C in PIIb: BI
April 18, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…